Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track PYPD with free AI briefings, catalyst countdowns, and dilution alerts.

PYPD · PolyPid Ltd.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$12.9M Cash on Hand

5.6mo Cash Runway

0.2% Short Interest

$12.25 Analyst Target (4)

Follow PYPD by email Get an email when PYPD pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PYPD, unsubscribe in one click. Privacy

📣 What PYPD Says Is Next

fourth quarter of 2026 · D-PLEX: “The Company successfully completed its New Drug Application (“NDA”) submission on a rolling review basis to the U.S. Food and Drug Administration (“FDA”) for D-PLEX 100 and anticipates a potential FDA decision in the fourth quarter of 2026 under the Prescription Drug User Fee Act review timeline.”
Company press release, Aug 12, 2026 · SEC filing
first quarter 2027 · D-PLEX: “The FDA did not identify any filing review issues and set a Prescription Drug User Fee Act (“PDUFA”) target action date of November 28, 2026, approximately one quarter ahead of the Company’s previously communicated first quarter 2027 guidance.”
Company press release, Jul 29, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

Apr 2025 · Phase 3 · Results Expected · D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Inc
Registry primary completion date, not a results date
Sep 2022 · Phase 3 · Results Expected · D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Inci
Registry primary completion date, not a results date
Sep 2019 · Phase 2 · Results Expected · D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Inci
Registry primary completion date, not a results date
Sep 2018 · NA · Results Expected · Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo I, II, IIIA and IIIB T
Registry primary completion date, not a results date
May 2018 · NA · Results Expected · BonyPid-500TM Bone Graft Substitute Study
Registry primary completion date, not a results date
Feb 2018 · Phase 1/2 · Results Expected · Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Doxycycline Hyclate Matrix Formulation	Surgical Site Infection	Phase 3 · NCT04411199	Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PYPD holds $12.9M in cash and short-term investments and burns about $7M/quarter from operations, an estimated runway of 5.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 85 · High

Cash runway 3 months +40
ATM program on file since Nov 2024 +15
Shelf registration (F-3, Jul 2024) +10
Share count +79% in a year +20

Recent financing filings on SEC EDGAR:

Nov 26, 2025 · Registered direct / best-efforts offering · 424B5
Nov 8, 2024 · ATM program, up to $8M · 424B5
Jul 2, 2024 · Shelf registration · F-3

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PYPD files for a raise →

👥 Who Owns PYPD

Insiders Form 4 data not loaded yet Institutions (38 holders) 34.6% Public and other holders 65.4%

Holder	Type	Shares	% of shares	As of
AIGH Capital Management LLC	Institution (13F)	1,342,972	7.38%	2025-12-31
Rosalind Advisors, Inc.	Institution (13F)	696,556	3.83%	2025-12-31
Morgan Stanley	Institution (13F)	208,278	1.14%	2025-12-31
DAFNA Capital Management, LLC	Institution (13F)	207,900	1.14%	2025-12-31
J. Goldman & Co., L.P.	Institution (13F)	172,310	0.95%	2025-12-31
Symmetry Peak Management LLC	Institution (13F)	127,326	0.70%	2025-12-31
Adar1 Capital Management, LLC	Institution (13F)	103,950	0.57%	2025-12-31
Lumbard & Kellner, LLC	Institution (13F)	38,200	0.21%	2025-12-31
Xtx Topco Ltd	Institution (13F)	32,661	0.18%	2025-12-31
Jane Street Group, LLC	Institution (13F)	15,199	0.08%	2025-12-31

Share count 18,204,002 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade date	Insider	Transaction	Shares	Price	Owned after
2026-07-15 filed 2026-07-17	Barenholz Yechezkel	Option award (A)	9,132	$4.46	–
2026-07-15 filed 2026-07-17	Dror-Darwish Nir	Option award (A)	9,132	$4.46	–
2026-07-15 filed 2026-07-17	BenAmram Joseph	Option award (A)	9,132	$4.46	–
2026-07-15 filed 2026-07-17	Story Brooke	Option award (A)	9,132	$4.46	–
2026-07-15 filed 2026-07-17	Akselbrad Dikla Czaczkes	Option award (A)	149,000	$4.46	–

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full PYPD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PYPD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z